---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-032774"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T01:50:04.685616+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protagonist reports Q4 net loss $0.69/shr, cash $237M; positive Ph2b JNJ-2113 and rusfertide REVIVE data

## Summary
- Net loss per share Q4 2022: $0.69 ($34.2M) vs $0.77 ($36.9M) in Q4 2021; full year 2022 net loss $127.4M.
- Cash, cash equivalents and marketable securities $237.4M at Dec 31, 2022; expected to fund operations through end of 2024.
- Phase 2b FRONTIER 1 study of JNJ-2113 in psoriasis met primary endpoint: statistically significant PASI-75 at Week 16 across all doses, well tolerated.
- Phase 2 REVIVE study of rusfertide in polycythemia vera met primary endpoint: proportion of responders on rusfertide vs placebo p=0.0003; 92.3% phlebotomy-free.
- License revenue from Janssen collaboration declined to zero in Q4 2022 as performance obligations completed June 2022; total milestones and royalties potential $855M.

## SEC filing metadata
- accession: 0001104659-23-032774
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/0001104659-23-032774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/tm239503d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-032774
- JSON: https://secwatch.observer/filing/0001104659-23-032774.json
- Plain text: https://secwatch.observer/filing/0001104659-23-032774.txt

## Key facts
- Earnings Releases
  Protagonist Therapeutics, Inc reported the fourth quarter ended December 31, 2022 results: revenue zero.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: zero
  - Result: reported results
  source text: License and Collaboration Revenue : License and collaboration revenue for the fourth quarter and full year 2022 were zero and $26.6 million, respectively, as compared to $8.6 million and $27.4 million for the same periods of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/0001104659-23-032774-index.htm
- Earnings Releases
  Protagonist Therapeutics, Inc reported the full year ended December 31, 2022 results: revenue $26.6 million.
  - Period: the full year ended December 31, 2022
  - Revenue: $26.6 million
  - Result: reported results
  source text: License and Collaboration Revenue : License and collaboration revenue for the fourth quarter and full year 2022 were zero and $26.6 million, respectively, as compared to $8.6 million and $27.4 million for the same periods of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923032774/0001104659-23-032774-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.